CVKD
Cadrenal Therapeutics, Inc.Company Information
- Company Name
- Cadrenal Therapeutics, Inc.
- CIK
- CIK0001937993
- Category
- <br>Emerging growth company
- Ticker: Exchange
- CVKD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CVKD
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-10-05
- Last sale
- 2026-06-29
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 72,071
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 83,424
- Shares outstanding
- 2,913,225
- Ownership
- 2.86%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -34.41%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 4 | 4 | 6 | 7 | 10 | 4 | 5 | 7 | 8 | 9 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Offering Costs | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Interest Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | - | - | - | 0 | - | ||||||
| Deferred Costs Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Assets Current | 6 | 3 | 4 | 4 | 6 | 8 | 10 | 5 | 5 | 7 | 8 | 9 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 6 | 3 | 4 | 4 | 6 | 8 | 10 | 5 | 5 | 7 | 9 | 9 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Liabilities | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 49 | 43 | 42 | 39 | 38 | 36 | 33 | 25 | 23 | 23 | 23 | 23 | ||||||
| Retained Earnings Accumulated Deficit | -45 | -41 | -39 | -36 | -33 | -30 | -26 | -22 | -19 | -17 | -15 | -14 | ||||||
| Stockholders Equity | 4 | 2 | 3 | 3 | 4 | 6 | 7 | 3 | 4 | 6 | 8 | 9 | ||||||
| Liabilities And Stockholders Equity | 6 | 3 | 4 | 4 | 6 | 8 | 10 | 5 | 5 | 7 | 9 | 9 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | - | 8 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||||
| Common Stock Shares Issued | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCadrenal Therapeutics, Inc. (CVKD) — SEC Financial Statements & Analysis
Cadrenal Therapeutics, Inc. (CVKD) is a pharmaceutical preparations company, incorporated in DE. Cadrenal Therapeutics, Inc. trades on Nasdaq as: CVKD. Cadrenal Therapeutics, Inc. (CVKD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Cadrenal Therapeutics, Inc. carries a market cap of $9.73M, a P/E ratio of -0.84x, a P/B ratio of 2.38x, an enterprise value of $7.34M, and an EV/EBITDA multiple of -0.63x. On profitability, it posts a Return on Equity (ROE) of -275.16%, a Return on Assets (ROA) of -199.59%, and a Return on Invested Capital (ROIC) of -5398.27%. Per share, it reports EPS of $-3.96, diluted EPS of $-3.96, free cash flow per share of $-3.49, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -18.17% year-over-year and EPS growth of -44.90% year-over-year. On the balance sheet, it maintains a current ratio of 3.73x, a quick ratio of 3.46x, working capital of $4.09M, a debt-to-equity ratio of 0.37x, a debt ratio of 0.27, an interest coverage ratio of -2159.83x, free cash flow of $-10.16M (TTM), and net debt of $-2.39M. Figures sourced from SEC EDGAR.
- Market Cap
- $9.73M
- P/E TTM
- -0.84x
- EPS TTM
- $-3.96
- P/B TTM
- 2.38x
- ROE TTM
- -275.16%
- ROA TTM
- -199.59%
- Debt To Equity
- 0.37x
- Free Cash Flow TTM
- $-10.16M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cadrenal Therapeutics, Inc. in?
Cadrenal Therapeutics, Inc. (CVKD) operates in the Pharmaceutical Preparations industry.
What exchange does CVKD trade on?
Cadrenal Therapeutics, Inc. (CVKD) trades on the Nasdaq.
Where is Cadrenal Therapeutics, Inc. incorporated?
Cadrenal Therapeutics, Inc. is incorporated in DE.
When was Cadrenal Therapeutics, Inc. (CVKD)'s most recent SEC filing?
Cadrenal Therapeutics, Inc. (CVKD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CVKD's market cap?
Cadrenal Therapeutics, Inc. (CVKD) has a market capitalization of $9.73M as of 2026-06-30.
What is CVKD's EPS (earnings per share)?
Cadrenal Therapeutics, Inc. (CVKD)'s trailing twelve month EPS is $-3.96 as of 2026-06-30.
What is CVKD's ROE (return on equity)?
Cadrenal Therapeutics, Inc. (CVKD)'s trailing twelve month Return on Equity (ROE) is -275.16% as of 2026-06-30.
What is CVKD's ROA (return on assets)?
Cadrenal Therapeutics, Inc. (CVKD)'s trailing twelve month Return on Assets (ROA) is -199.59% as of 2026-06-30.
What is CVKD's ROIC (return on invested capital)?
Cadrenal Therapeutics, Inc. (CVKD)'s trailing twelve month Return on Invested Capital (ROIC) is -5398.27% as of 2026-06-30.
What is CVKD's EV/EBITDA?
Cadrenal Therapeutics, Inc. (CVKD)'s trailing twelve month EV/EBITDA is -0.63x as of 2026-06-30.